TDC
STAB

Thompson Davis & Co’s Statera Biopharma, Inc. Common Stock STAB Stock Holding History

Thompson Davis & Co’s Portfolio STAB Stock Details STAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-1,334
Closed -$5K – 1144
2017
Q3 		$5K Buy
1,334
+334
+33% +$945 0.01% 865
2017
Q2 		$3K Buy
+1,000
New +$3.27K ﹤0.01% 955
2015
Q4 		– Sell
-1,800
Closed -$8K – 1208
2015
Q3 		$8K Buy
+1,800
New +$7.32K 0.01% 741
2014
Q3 		– Sell
-250
Closed – – 1261
2014
Q2 		$0 Buy
+250
New +$2.92K ﹤0.01% 880

Other funds holding STAB

Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PAM
Panagora Asset Management Boston, Massachusetts $26.7B AUM 36.4% 1-Year Est. Return
WA
Winfield Associates Cleveland, Ohio $276M AUM 15.18% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Thompson Davis & Co's STAB Position: Q4 2017 in Review

Thompson Davis & Co sold out of Statera Biopharma, Inc. Common Stock (STAB) in Q4 2017, closing a stake of 1,334 shares — an estimated $5K sold.

Thompson Davis & Co first reported a position in STAB in Q2 2014 and held it in 4 quarters. The position peaked at $8K in Q3 2015. 18 funds tracked by Wall St. Rank hold STAB as of Q4 2017.

  • Thompson Davis & Co reported no remaining Statera Biopharma, Inc. Common Stock position as of Q4 2017 after selling out during the quarter.
  • Thompson Davis & Co sold 1,334 Statera Biopharma, Inc. Common Stock shares in Q4 2017, an estimated $5K.
  • Thompson Davis & Co first reported a position in Statera Biopharma, Inc. Common Stock in Q2 2014 and held it in 4 quarters.
  • Thompson Davis & Co's Statera Biopharma, Inc. Common Stock position peaked at $8K in Q3 2015.
  • 18 funds tracked by Wall St. Rank held Statera Biopharma, Inc. Common Stock as of Q4 2017.

Based on Thompson Davis & Co's 13F filing for Q4 2017, filed 5 Feb 2018.